Form 4: GRI Bio Director Granted Stock Options
Insider Transaction Report
GRI Bio, Inc. Director David Charles Baker was granted 5,994 stock options with an exercise price of $1.41, vesting over one year.
Summary
- David Charles Baker, a Director of GRI Bio, Inc., was granted 5,994 stock options.
- The options have an exercise price of $1.41 per share.
- The options expire on August 26, 2035.
- 4,044 of the options vested immediately upon the grant date of August 26, 2025.
- The remaining 1,950 options will vest in four equal quarterly installments, becoming fully vested on the first anniversary of the grant date, August 26, 2026.
Sentiment
Score: 5
Explanation: A routine grant of stock options to a director is a neutral event, reflecting standard compensation practices without significant positive or negative implications for the company's immediate financial health or strategic direction.
Positives
- The grant of stock options aligns the director's interests with long-term shareholder value.
- The vesting schedule encourages continued service and performance from the director.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Structure | Grant of stock options to Director David Charles Baker as part of his compensation. | 08/26/2025 | Aligns director's incentives with long-term shareholder value through equity ownership and a vesting schedule. |
Stakeholder Impact
- Shareholders: Potential for increased alignment of the director's interests with long-term shareholder value due to equity ownership and performance incentives.
Next Steps
- The remaining 1,950 options will vest in four substantially equal quarterly installments until August 26, 2026.
Key Dates
| Date | Description |
|---|---|
| 08/26/2025 | Date of stock option grant and immediate vesting for 4,044 shares. |
| 08/26/2026 | Date by which all 5,994 stock options will be fully vested. |
| 08/26/2035 | Expiration date of the granted stock options. |
Keywords
GRI Bio, GRI, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, David Charles Baker
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.